Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.

Xia-Hong YouYu-Huan JiangZhou FangFan SunYao LiWei WangZi-Jin XiaXiao-Zhong WangHou-Qun Ying

Published in: ESMO open (2020)

Patients with right-sided mCRC show impaired chemosensitivity, and chemotherapy plus bevacizumab can be an optimal first-line therapeutic regimen for the RAS-wild patients with right-sided mCRC.

Keyphrases

clinical trial
locally advanced
metastatic colorectal cancer
squamous cell carcinoma
small cell lung cancer
randomized controlled trial
chemotherapy induced
study protocol
open label
genetic diversity